On March 22, 2021 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, reported that it will be added to the Russell 2000 Index effective March 22, 2021, as part of its quarterly initial public offering (IPO) additions (Press release, Sensei Biotherapeutics, MAR 22, 2021, View Source [SID1234576960]). The Russell 2000 Index measures the performance of the small cap segment of the U.S. equity market. Membership in the Russell 2000 provides automatic inclusion in the appropriate growth and value style indexes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Russell U.S. Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes. Russell U.S. Indexes are part of FTSE Russell, a leading global index provider. For more information about the Russell U.S. Indexes and the Russell Indexes reconstitution, visit the FTSE Russell website.